Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,101–1,200 of 2,039
Hu, S., Shi, C., Ma, Y., Wang, S., Gu, S., Qi, C., & Fan, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15645 · Cited by 4
Trialing precision medicine for type 2 diabetes
Pilla, S. J., Mathioudakis, N. N., & Maruthur, N. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02168-5 · Cited by 6
Papadopoulou, A., & Papadopoulos, K. I. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.347 · Cited by 7
Prieto, B. L. A., & Lozano, E. W. M. (2001) · Repositorio Institucional Universidad Católica de Colombia (Universidad Católica de Colombia) · Cited by 6
NESTOR, J. J. J., Parkes, D. G., Feigh, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1547397/v1 · Cited by 4
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch09 · Cited by 6
Treatment of Obesity in Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.016 · Cited by 3
De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
Phan, F., Bertrand, R., Amouyal, C., & Andréelli, F. (2024) · médecine/sciences · doi:10.1051/medsci/2024153 · Cited by 4
Baran, K., Jankowska, M., Jańczyk, N., Mędrysa, K., Pokrzepa, J. J., Presak, M., Blecharz, G., Szwech, J., Winkowska, A., & Machalica, J. (2024) · Quality in Sport · doi:10.12775/qs.2024.30.56469 · Cited by 4
Arietti, P., Boye, K. S., Guidi, M., Rachman, J., Federici, M. O., Raiola, R., Avitabile, A., & Valentine, W. J. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01553-w · Cited by 3
Management of Diabetes in Patients with Chronic Kidney Disease
Ambalavanan, J., & Caramori, M. L. (2025) · Endocrine Research · doi:10.1080/07435800.2025.2473896 · Cited by 5
Cardiometabolic health and ASCVD primary prevention: time to take actions
Liu, J. (2025) · npj Cardiovascular Health · doi:10.1038/s44325-025-00050-0 · Cited by 3
Safety and Effectiveness of Tirzepatide in Solid-Organ Transplant Recipients
Sweiss, H., Flores, R., Windler, S., Hall, R., Bhayana, S., Patel, R., & Long, C. M. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0071 · Cited by 5
Wang, J., Kang, J., Peng, T., Chen, H., Chen, S., & Lee, M. (2025) · Clinical Obesity · doi:10.1111/cob.70036 · Cited by 5
“In the SURPASS-2 study [28], tirzepatide outperformed 1 mg of Semaglutide in both glycemic control and weight reduction across its 5, 10, and 15 mg doses.”
Kanu, C., Boye, K. S., Poon, J. L., GOETZ, I. A., WILLIAMSON, S. E., Lou, J., Hartman, M. L., Martin, C. K., & Coşkun, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70097 · Cited by 6
New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review
Doroba, O., Czupryniak, L., Sanfilippo, F., Andruszkiewicz, P., & Zawadka, M. (2025) · Anaesthesiology Intensive Therapy · doi:10.5114/ait/208895 · Cited by 6
The role of the incretin GIP in inflammation
Rossi, G., Bucciarelli, L. G., Cimino, V., & Fiorina, P. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02719-w · Cited by 7
Tanaka, M., & Itoh, H. (2025) · International Summit on Diabetes, Endocrinology and Metabolic Disorders · doi:10.1038/s41440-025-02418-2 · Cited by 3
Balakumar, P., Mulukuri, N. V. L. S., & Jagadeesh, G. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108945 · Cited by 7
Jayathilaka, N. S., Weththasinghe, A. V., Ganamurali, N., & Sabarathinam, S. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1624 · Cited by 3
Rahman, M. H., Selim, S., Afsana, F., Hoque, M. A., Saifuddin, M., Alam, M. S., Sharifuzzaman, M., Tareq, M. A. H., Hasan, M. N., Kamrul-Hasan, A. B. M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70343 · Cited by 5
Ezenekwe, L., & Newberry, C. A. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.70074 · Cited by 3
“54 , 61 Many GI side effects occurred There also exists a theoretical risk of GI or other obesity ‐ associated malignancy.”
Car, M., Erceg, D., Udovičić, M., Bokun, T., & Rahelić, D. (2025) · Medicina · doi:10.3390/medicina61122210 · Cited by 4
Bittencourt, J. D. O. A., Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124155 · Cited by 3
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
“%) and body weight (up to − 12.9 kg) compared with placebo, semaglutide, or insulin comparators (Rosenstock et al. 2023; Rosenstock, et al. 2020; Frias et al. 2021; Ludvik et al. 2021; Del Prato et al. 2021; Dahl et al. 2022).”
InfluentialNew-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report
Purvez, A., Mirza, M., & Bashir, M. (2025) · Cureus · doi:10.7759/cureus.99651 · Cited by 3
Abusedera, O., Sherif, J., Smida, M., & Fredericks, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248734 · Cited by 5
“Tirzepatide appears to improve beta-cell function more significantly than semaglutide, likely due to its dual receptor function [31,38,39].”
El‐Amawy, H. S. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2025.501255 · Cited by 11
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
AlQarni, B. S., Aldadi, S., & Alotaibi, A. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102485 · Cited by 3
Panunzi, S., Russo, S. L. M. L., Pompa, M., Gaetano, A. D., Verrastro, O., Tuccinardi, D., Guidone, C., Castagneto‐Gissey, L., Casella, G., Mariolo, J. R. C., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156495 · Cited by 5
Obesity and Its Clinical Implications in End-Stage Kidney Disease
Petrulienė, K., Žilinskienė, A., Vaičiūnienė, R., Vaičiūnas, K., Bumblytė, I. A., & Dalinkevičienė, E. (2026) · Medicina · doi:10.3390/medicina62010211 · Cited by 3
Yen, Y., Zhang, Q., Yin, S., Pu, Y., Song, K., Song, X., Shen, X., Wan, Q., Zhao, R., Zhang, G., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04648-8 · Cited by 7
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“…endpoint in patients with type 2 diabetes mellitus (T2DM), especially when compared to placebo ( SURPASS 1 ), [94] semaglutide 1 mg ( SURPASS 2 ), [95] insulin degludec as an add-on to metformin with or without SGLT2 inhibitor ( SURPASS 3 ), [96] insulin glargine ( SURPASS 4 ), [97] and placebo +…”
Self-citationKumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Management of the kidney transplant candidate with obesity
Abbasi, A. B., & Orandi, B. J. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001266 · Cited by 3
Chadwick, J., Sivamani, C., Lakshmi, S., Vishali, B., Swathi, N. L., Ayyasamy, L., Ganeshkumar, P., & Bagepally, B. S. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08508-5 · Cited by 5
Zufry, H., & Hariyanto, T. I. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.02.002 · Cited by 9
Hitaka, K., Sugawara, T., Matsumoto, M., & Nio, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02025-2 · Cited by 3
d’Aquino, A. I., Dong, C., Nguyen, L. T., Yan, J., Jons, C. K., Saouaf, O. M., Song, Y. E., Eckman, N., Kapasi, S., Williams, C. M., et al. (2026) · Advanced Therapeutics · doi:10.1002/adtp.202500329 · Cited by 9
Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy
Mandour, M. O., Stears, A. J., van der Klaauw, A. A., Flanagan, C., Gaff, L., Jenkins, C., & Savage, D. B. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag126 · Cited by 4
Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass
Castelletto, V., de Mello, L. R., Seitsonen, J. J. T., & Hamley, I. W. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.5c02669 · Cited by 3
Drug-induced liver injury secondary to tirzepatide
Cao, C., Subhaharan, D., Mikhail-Gouda, P., & Haig, A. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-269172 · Cited by 4
Maruyama, F., Kitsunai, H., Kitao, N., Wakabayashi, Y., Ito, M., Kurihara, H., Yamamoto, K., Takeuchi, J., Abiko, A., Homma, R., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70734 · Cited by 4
“The rate of reduction in HbA1c with tirzepatide in each of the SURPASS studies was generally around 2% [16, 20–23], which is greater than in the present study.”
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Angelopoulos, N., Zianni, D., Livadas, S., Androulakis, I., Fousteris, E., Paparodis, R. D., Petkova, V., Florakis, D., Mouslech, Z., Rizoulis, A. A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70810 · Cited by 6
“In randomised controlled trials, tirzepatide has demonstrated significant efficacy in body weight reduction and metabolic improvement compared with established GLP-1 receptor agonists [7–9].”
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
Obstructive Sleep Apneas and Cardiovascular Diseases
Castiglione, V., Morfino, P., Fabiani, I., Gentile, F., Airò, E., Volpi, B., Cardinale, D. M., Passino, C., Giannoni, A., & Emdin, M. (2026) · Clocks & Sleep · doi:10.3390/clockssleep8020028 · Cited by 7
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Naik, H. B., & Thiara, D. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.1882 · Cited by 3
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Dennis, C. J., He, A. Z., Krishnaraj, A., Quan, A., Teoh, H., Connelly, K. A., Hess, D. A., & Verma, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327425 · Cited by 4
Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., Nielsen, C. K., Forman, J. L., Christensen, M., & Knop, F. K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065736 · Cited by 3
How far are we from an approved drug for nonalcoholic steatohepatitis?
Méndez‐Sánchez, N., Pal, S. C., & Córdova‐Gallardo, J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206953 · Cited by 3
Jiang, P., Sun, N., Yang, W. Y., Xiao, L., Zhou, L., Gu, B., Li, Y., Li, L., Li, J., Li, X., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15235 · Cited by 3
“7%).(9) Hence, the synergistic effect of GLP-1R/GIPR dual agonists in glycaemic con-”
BackgroundDual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence
Wardeh, R., Elbo-Iswadi, T. H., Alsharayri, H. M. H., Rashid, F., Alhashemi, N., & Bashier, A. M. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1775966 · Cited by 6
Rangwala, H. S., Fatima, H., Ali, M., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., & Abbas, S. R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01412-8 · Cited by 3
Bauri, R., Bele, S. D., Edelli, J., Reddy, N. C., Kurukuti, S., Devasia, T., Ibrahim, A., Rai, V., & Mitra, P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2023 · Cited by 4
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
Freschi, M. L., Künstner, A., Huber, G., Stölting, I., Busch, H. S., Hirose, M., & Raasch, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1453989 · Cited by 3
Shestakova, E. A., Stafeev, I., Yashkov, Y., Yurasov, A., Tomilova, A., Parfyonova, Y. V., Shestakova, M. V., & Dedov, I. I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226998 · Cited by 4
Takyi, A. K., Gaffey, R. H., & Shukla, A. P. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00465-1 · Cited by 4
Triple Agonist Therapy: A New Frontier in Treating Type 2 Diabetes and Obesity
Whitley, H. P. (2025) · Clinical Diabetes · doi:10.2337/cd25-0018 · Cited by 3
Understanding Diabetes Remission
Velayutham, K., Panneerselvam, G., & Ramanathan, B. (2025) · Apollo Medicine · doi:10.1177/09760016251323727 · Cited by 4
“[51] s urgIcal I nterventIon Bariatric surgery, particularly weight loss methods such as Roux-en-Y gastric bypass, adjustable gastric banding and sleeve gastrectomy are powerful procedures to achieve long-term remission in T2D with severe obesity.”
Dsouza, P. D., Chitralu, S. P. P., Khan, R., & Nyamagoud, S. B. (2025) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_386_24 · Cited by 3
Emerging therapeutic frontiers in hypertension management
Pena, D.-L., Aurelian, J., Grigore, M., Hodorogea, A. S., Weiss, E., Bădilă, E., Ilieșiu, A.-M., & Balahura, A.-M. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1550181 · Cited by 5
Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
Bobok, N. M. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.3.2025.1544 · Cited by 4
A case of euglycaemic diabetic ketoacidosis in a T2DM patient using Tirzepatide
Chaudhury, N., Baslas, R., & Bhamra, K. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf079 · Cited by 3
Arai, T., Atsukawa, M., Nagao, C., Yamada, Z., Rokugo, T., Suzuki, K. M., Kitamura, M., Higashi, T., Koyano, K., Hasegawa, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14241 · Cited by 8
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Pardeshi, G. S., Kumbhar, U. T., Kaviprawin, M., Debnath, A., Dubey, A. K., Deshmukh, K., Goyal, C., & Gandhi, A. P. (2025) · Clinical Obesity · doi:10.1111/cob.70042 · Cited by 4
“Importantly, Tirzepatide has demonstrated robust improvements in markers of glycemic control, including fasting plasma glucose, HbA1c levels and beta-cell function [11].”
InfluentialColorado, M., Miranda, J. G., & Arias-Morales, C. E. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf195 · Cited by 3
El-Wakil, E. S., El-Maadawy, W. H., Bayomy, A. A., Shakra, M. Y., Mohamed, A. M. A., Mostafa, M. E. S., & Helal, H. S. (2025) · Research in Veterinary Science · doi:10.1016/j.rvsc.2025.105895 · Cited by 3
The dawning of dual-acting incretin drugs
Starling, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00540-y · Cited by 3
Twincretin therapy for type 2 diabetes: how do two do?
Rayner, C. K., & Horowitz, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01597-x · Cited by 4
Druzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4755 · Cited by 5
Fernández, M. G. M., Chamik, E. R. T., Rivera, V. M. L., Delgado, M. C. R., Feijoó, A. C. S., & Aguinsaca, K. F. P. (2023) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v7i1.4596 · Cited by 8
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00409-1 · Cited by 5
Bhattacharya, S., & Kalra, S. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.2.1 · Cited by 3
“polypeptide and GLP1 RA, has even less relevance in the AfroAsian context due to its cost and lack of availability.(15) Furthermore, as discussed, lean and underweight individuals comprise a”
BackgroundSURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
Frandsen, C. S., & Madsbad, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01292-8 · Cited by 3
Tirzepatide – a new analogue of incretin hormones
Anglart, G., Janik, L., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/174068 · Cited by 3
Rodrigues, M. F. G., Araújo, A. H. M., Oliveira, F. C. M., Leal, I. B. F., Andrade, I. F. D., & de Sousa, M. N. A. (2023) · Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida · doi:10.36692/v15n3-56r · Cited by 6
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond
Sood, A., Kaur, P., Syed, O., Sood, A., Aronow, W. S., Borokhovsky, B., Bhatia, V., & Gupta, R. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2310070 · Cited by 4
Tirzepatide, a dual incretin analog, is a boon in metabolic syndrome: an editorial
Bardhan, M., Gokhale, P., Roy, P., Kundu, T., & Anand, A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001782 · Cited by 3
“In SURPASS [1,2,5] and SURMOUNT-1 trials [6] and SURPASS J-mono sub-trial [7] , tirzepatide showed a substantial decrease in body weight.”
BackgroundMethodHachem, M., Hearn, T., Kelly, R. D., Eer, A., Moore, B., Sommerville, C., Atkinson‐Briggs, S., Twigg, S. M., Freund, M., O'Neal, D. N., et al. (2024) · Trials · doi:10.1186/s13063-024-08267-7 · Cited by 4
Fujihara, K., Matsubayashi, Y., Kitazawa, M., Sato, T., Takeuchi, M., Oura, T., & Sone, H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15887 · Cited by 5
Ala, M., Jafari, R. M., Dehpour, A. R., & Poursalehian, M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01621-4 · Cited by 7
Cremona, S., Llerena, G. C., de Hollanda, A., Robles, C. J., Pagano, G., Ibarzabal, A., Hernández-Évole, H., Fundora, Y., & Crespo, G. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07553-2 · Cited by 3
Current status of anti-obesity medications and performance, an EHR based survey
Ruan, X., Li, R., Wang, L., Lu, S., Wen, A., Murali, S. B., & Liu, H. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02423-7 · Cited by 3
Tirzepatide in Treating Metabolic Disorders
Wei, S., & Xu, S. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100023 · Cited by 4
Lahey, A. M., Duprey, K. S., Montague, R. C., Schadler, A. D., & Naseman, K. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70009 · Cited by 6
Blum, K., Dennen, C. A., Lewandrowski, K.-U., Sharafshah, A., Pinhasov, A., Bowirrat, A., Elman, I., Cadet, J. L., Braverman, E. R., Thanos, P. K., et al. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111612 · Cited by 4
Dorothy Hodgkin lecture 2023: The enteroendocrine system—Sensors in your guts
Reimann, F. M. (2023) · Diabetic Medicine · doi:10.1111/dme.15212 · Cited by 2
“…drugs such as tirzepatide, however, combine GLP1R agonism with GIPR agonism and have even more profound effects on body weight and blood glucose, 10 and so-called triple agonists combining GLP-1, GIP and glucagon receptor activity are currently under development that show even greater promise…”
BackgroundNovel approaches to pharmacological management of type 2 diabetes in Japan
Kaneko, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1974401 · Cited by 6
“Semaglutide, as well as other GLP-1 R agonists, has anti-inflammatory activity (class effect) [61], and is”
BackgroundGelhorn, H. L., Ross, M., Shinde, S., Thieu, V. T., & Boye, K. S. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s366966 · Cited by 3
Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
Chiu, N., Aggarwal, R., & Bhatt, D. L. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026297 · Cited by 4
Pharmacotherapy in obesity: the current state and the near future
Cho, Y. J., & Kim, K. K. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.8.514 · Cited by 3
Perreault, L., & Bergman, B. C. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13505 · Cited by 3
Self-citationBitsi, S., Manchanda, Y., Eid, L. E., Mohamed, N., Hansen, B., Suba, K., Rutter, G. A., Salem, V., Jones, B. J., & Tomás, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.21.489075 · Cited by 3
“Importantly, the clinical relevance of our observations is clearly established as the currently leading, as well as the most promising pharmacological GLP-1RAs, namely semaglutide and tirzepatide (47), were both similarly affected to exendin-4 by the lack of beta cell β-arrestin 2.”
BackgroundHorowitz, M., Cai, L., & Islam, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.326 · Cited by 3
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.